69 results on '"Cortis, Elisabetta"'
Search Results
52. Infliximab therapy in pediatric Takayasu’s arteritis: report of two cases
- Author
-
Buonuomo, Paola Sabrina, primary, Bracaglia, Claudia, additional, Campana, Andrea, additional, Insalaco, Antonella, additional, Pardeo, Manuela, additional, Cortis, Elisabetta, additional, and Ugazio, Alberto G., additional
- Published
- 2009
- Full Text
- View/download PDF
53. Differentiating PFAPA Syndrome From Monogenic Periodic Fevers
- Author
-
Gattorno, Marco, primary, Caorsi, Roberta, additional, Meini, Antonella, additional, Cattalini, Marco, additional, Federici, Silvia, additional, Zulian, Francesco, additional, Cortis, Elisabetta, additional, Calcagno, Giuseppina, additional, Tommasini, Alberto, additional, Consolini, Rita, additional, Simonini, Gabriele, additional, Pelagatti, Maria Antonietta, additional, Baldi, Maurizia, additional, Ceccherini, Isabella, additional, Plebani, Alessandro, additional, Frenkel, Joost, additional, Sormani, Maria Pia, additional, and Martini, Alberto, additional
- Published
- 2009
- Full Text
- View/download PDF
54. Relapsing polychondritis: new therapeutic strategies with biological agents
- Author
-
Buonuomo, Paola Sabrina, primary, Bracaglia, Claudia, additional, Campana, Andrea, additional, El Hachem, Maya, additional, Diociaiuti, Andrea, additional, Insalaco, Antonella, additional, De Benedetti, Fabrizio, additional, Testa, Beatrice Chiarini, additional, Cortis, Elisabetta, additional, De Vincentiis, Giovanni Carlo, additional, and Ugazio, Alberto G., additional
- Published
- 2009
- Full Text
- View/download PDF
55. Pigmented villonodular synovitis in a patient with Noonan syndrome andSOS1gene mutation
- Author
-
Mascheroni, Elisabetta, primary, Digilio, M. Cristina, additional, Cortis, Elisabetta, additional, Devito, Rita, additional, Sarkozy, Anna, additional, Capolino, Rossella, additional, Dallapiccola, Bruno, additional, and Ugazio, Alberto G., additional
- Published
- 2008
- Full Text
- View/download PDF
56. Macrophage activation syndrome in juvenile idiopathic arthritis
- Author
-
Cortis, Elisabetta, primary and Insalaco, Antonella, additional
- Published
- 2007
- Full Text
- View/download PDF
57. Longterm outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients
- Author
-
Ravelli, Angelo, Trail, Lucia, Ferrari, Cristina, Ruperto, Nicolino, Pistorio, Angela, Pilkington, Clarissa, Maillard, Susan, Oliveira, Sheila K., Sztajnbok, Flavio, Cuttica, Ruben, Beltramelli, Matilde, Corona, Fabrizia, Katsicas, Maria Martha, Russo, Ricardo, Ferriani, Virginia, BurgosVargas, Ruben, MagniManzoni, Silvia, SolisValleoj, Eunice, Bandeira, Marcia, Zulian, Francesco, Baca, Vicente, Cortis, Elisabetta, Falcini, Fernanda, Alessio, Maria, Alpigiani, Maria Giannina, Gerloni, Valeria, SaadMagalhaes, Claudia, Podda, Rosanna, Silva, Clovis A., Lepore, Loredana, Felici, Enrico, Rossi, Federica, Sala, Elena, and Martini, Alberto
- Abstract
ObjectiveTo investigate the longterm outcome and prognostic factors of juvenile dermatomyositis DM through a multinational, multicenter study.MethodsPatients consisted of inception cohorts seen between 1980 and 2004 in 27 centers in Europe and Latin America. Predictor variables were sex, continent, ethnicity, onset year, onset age, onset type, onset manifestations, course type, disease duration, and active disease duration. Outcomes were muscle strengthendurance, continued disease activity, cumulative damage, muscle damage, cutaneous damage, calcinosis, lipodystrophy, physical function, and healthrelated quality of life HRQOL.ResultsA total of 490 patients with a mean disease duration of 7.7 years were included. At the crosssectional visit, 41.2–52.8 of patients, depending on the instrument used, had reduced muscle strengthendurance, but less than 10 had severe impairment. Persistently active disease was recorded in 41.2–60.5 of the patients, depending on the activity measure used. Sixtynine percent of the patients had cumulative damage. The frequency of calcinosis and lipodystrophy was 23.6 and 9.7, respectively. A total of 40.7 of the patients had decreased functional ability, but only 6.5 had major impairment. Only a small fraction had decreased HRQOL. A chronic course, either polycyclic or continuous, consistently predicted a poorer outcome. Mortality rate was 3.1.ConclusionThis study confirms the marked improvement in functional outcome of juvenile DM when compared with earlier literature. However, many patients had continued disease activity and cumulative damage at followup. A chronic course was the strongest predictor of poor prognosis. These findings highlight the need for treatment strategies that enable a better control of disease activity over time and the reduction of nonreversible damage.
- Published
- 2010
- Full Text
- View/download PDF
58. The Pediatric Rheumatology International Trials OrganizationAmerican College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvementThis criteria set has been approved by the American College of Rheumatology ACR Board of Directors as Provisional. This signifies that the criteria set has been quantitatively validated using patient data, but it has not undergone validation based on an external data set. All ACRapproved criteria sets are expected to undergo intermittent updates.The American College of Rheumatology is an independent, professional, medical, and scientific society which does not guarantee, warrant, or endorse any commercial product or service.
- Author
-
Ruperto, Nicolino, Ravelli, Angelo, Oliveira, Sheila, Alessio, Maria, Mihaylova, Dimitrina, Pasic, Srdjan, Cortis, Elisabetta, Apaz, Maria, Burgosvargas, Ruben, Kanakouditsakalidou, Florence, Norambuena, Ximena, Corona, Fabrizia, Gerloni, Valeria, Hagelberg, Stefan, Aggarwal, Amita, Dolezalova, Pavla, Saad, Claudia Magalhaes, Bae, Sangcheol, Vesely, Richard, Avcin, Tadej, Foster, Helen, Duarte, Carolina, HerliN, Troels, Horneff, Gerd, Lepore, Loredana, Rossum, Marion van, Trail, Lucia, Pistorio, Angela, AnderssonGäre, Boel, Giannini, Edward H., and Martini, Alberto
- Abstract
ObjectiveTo use the Pediatric Rheumatology International Trials Organization PRINTO core set of outcome measures to develop a validated definition of improvement for the evaluation of response to therapy in juvenile systemic lupus erythematosus SLE.MethodsThirtyseven experienced pediatric rheumatologists from 27 countries, each of whom had specific experience in the assessment of juvenile SLE patients, achieved consensus on 128 patient profiles as being clinically improved or not improved. Using the physicians consensus ratings as the gold standard measure, the chisquare, sensitivity, specificity, falsepositive and falsenegative rates, area under the receiver operating characteristic curve, and kappa level of agreement for 597 candidate definitions of improvement were calculated. Only definitions with a kappa value greater than 0.7 were retained. The top definitions were selected based on the product of the content validity score multiplied by its kappa statistic.ResultsThe definition of improvement with the highest final score was at least 50 improvement from baseline in any 2 of the 5 core set measures, with no more than 1 of the remaining worsening by more than 30.ConclusionPRINTO proposes a valid and reproducible definition of improvement that reflects well the consensus rating of experienced clinicians and that incorporates clinically meaningful change in core set measures in a composite end point for the evaluation of global response to therapy in patients with juvenile SLE. The definition is now proposed for use in juvenile SLE clinical trials and may help physicians to decide whether a child with SLE responded adequately to therapy.
- Published
- 2006
- Full Text
- View/download PDF
59. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvementThis criteria set has been approved by the American College of Rheumatology (ACR) Board of Directors as Provisional. This signifies that the criteria set has been quantitatively validated using patient data, but it has not undergone validation based on an external data set. All ACR‐approved criteria sets are expected to undergo intermittent updates.The American College of Rheumatology is an independent, professional, medical, and scientific society which does not guarantee, warrant, or endorse any commercial product or service.
- Author
-
Ruperto, Nicolino, Ravelli, Angelo, Oliveira, Sheila, Alessio, Maria, Mihaylova, Dimitrina, Pasic, Srdjan, Cortis, Elisabetta, Apaz, Maria, Burgos‐vargas, Ruben, Kanakoudi‐tsakalidou, Florence, Norambuena, Ximena, Corona, Fabrizia, Gerloni, Valeria, Hagelberg, Stefan, Aggarwal, Amita, Dolezalova, Pavla, Saad, Claudia Magalhaes, Bae, Sang‐cheol, Vesely, Richard, Avcin, Tadej, Foster, Helen, Duarte, Carolina, HerliN, Troels, Horneff, Gerd, Lepore, Loredana, Rossum, Marion van, Trail, Lucia, Pistorio, Angela, Andersson‐Gäre, Boel, Giannini, Edward H., and Martini, Alberto
- Abstract
To use the Pediatric Rheumatology International Trials Organization (PRINTO) core set of outcome measures to develop a validated definition of improvement for the evaluation of response to therapy in juvenile systemic lupus erythematosus (SLE).Thirty‐seven experienced pediatric rheumatologists from 27 countries, each of whom had specific experience in the assessment of juvenile SLE patients, achieved consensus on 128 patient profiles as being clinically improved or not improved. Using the physicians' consensus ratings as the gold standard measure, the chi‐square, sensitivity, specificity, false‐positive and false‐negative rates, area under the receiver operating characteristic curve, and kappa level of agreement for 597 candidate definitions of improvement were calculated. Only definitions with a kappa value greater than 0.7 were retained. The top definitions were selected based on the product of the content validity score multiplied by its kappa statistic.The definition of improvement with the highest final score was at least 50% improvement from baseline in any 2 of the 5 core set measures, with no more than 1 of the remaining worsening by more than 30%.PRINTO proposes a valid and reproducible definition of improvement that reflects well the consensus rating of experienced clinicians and that incorporates clinically meaningful change in core set measures in a composite end point for the evaluation of global response to therapy in patients with juvenile SLE. The definition is now proposed for use in juvenile SLE clinical trials and may help physicians to decide whether a child with SLE responded adequately to therapy.
- Published
- 2006
- Full Text
- View/download PDF
60. Necrosis of the tongue as first symptom of Polyarteritis Nodosa (PAN): unusual presentation of a rare disease in children.
- Author
-
Buonuomo, Paola, El Hachem, May, Callea, Francesco, Bracaglia, Claudia, Diociaiuti, Andrea, Pardeo, Manuela, Campana, Andrea, Insalaco, Antonella, Cortis, Elisabetta, and Ugazio, Alberto
- Subjects
POLYARTERITIS nodosa ,COLLAGEN diseases ,JUVENILE diseases ,TONGUE ,NECROSIS - Abstract
Polyarteritis or panarteritis nodosa (PAN) is a necrotizing, focal segmental vasculitis that affects predominantly medium-sized arteries in many different organ systems. It is extremely rare in childhood. Involvement of the oral mucosa at diagnosis is uncommon in PAN. Here, we report a case of a pediatric patient with tongue necrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
61. Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey
- Author
-
Ravelli, Angelo, Sinigaglia, Luigi, Cimaz, Rolando, Alessio, Maria, Breda, Luciana, Cattalini, Marco, Consolaro, Alessandro, Conti, Fabrizio, Cortis, Elisabetta, D Angelo, Salvatore, Benedetti, Fabrizio, Doria, Andrea, Ferrari, Claudia, Gallizzi, Romina, Govoni, Marcello, Gremese, Elisa, Iannone, Florenzo, La Torre, Francesco, Maggio, Maria Cristina, Perricone, Roberto, Pontikaki, Irene, Rossi, Fulvia, Salaffi, Fausto, Gabriele Simonini, Caporali, Roberto, Ravelli, A., Sinigaglia, L., Cimaz, R., Alessio, M., Breda, L., Cattalini, M., Consolaro, A., Conti, F., Cortis, E., D'Angelo, S., De Benedetti, F., Doria, A., Ferrari, C., Gallizzi, R., Govoni, M., Gremese, E., Iannone, F., La Torre, F., Maggio, M. C., Perricone, R., Pontikaki, I., Rossi, F., Salaffi, F., Simonini, G., Caporali, R., Ravelli A., Sinigaglia L., Cimaz R., Alessio M., Breda L., Cattalini M., Consolaro A., Conti F., Cortis E., D'Angelo S., De Benedetti F., Doria A., Ferrari C., Gallizzi R., Govoni M., Gremese E., Iannone F., La Torre F., Maggio M.C., Perricone R., Pontikaki I., Rossi F., Salaffi F., Simonini G., and Caporali R.
- Subjects
Adult ,Transition to Adult Care ,Settore MED/16 - REUMATOLOGIA ,paediatric rheumatic diseases ,Consensus ,Adolescent ,Juvenile ,Socio-culturale ,Child ,Humans ,Italy ,Surveys and Questionnaires ,Arthritis, Juvenile ,Rheumatology ,Transitional Care ,juvenile idiopathic arthritis, paediatric rheumatic diseases, Delphi survey, recommendations, transitional care, young peopleAdolescent, Adult, Child, Consensus, Humans, Italy, Surveys and Questionnaires, Arthritis, Juvenile, Rheumatology, Transition to Adult Care, Transitional Care ,young people ,Settore MED/38 - Pediatria Generale E Specialistica ,young peopleAdolescent ,LS7_9 ,Arthritis ,recommendations ,juvenile idiopathic arthritis ,Delphi survey ,juvenile idiopathic arthritis, paediatric rheumatic diseases, Delphi survey, recommendations, transitional care, young people - Abstract
OBJECTIVES: To present the results of a Delphi consensus survey among Italian paediatric and adult rheumatologists on transitional care (TC) of young people (YP) with juvenile idiopathic arthritis (JIA). METHODS: A taskforce of 27 paediatric and adult rheumatologists evaluated the applicability of the 2016 EULAR/PReS recommendations for TC to the Italian rheumatology practice and healthcare system and formulated additional country-specific statements aimed to increase their suitability. After a two-round discussion, applicability of EULAR/PReS recommendations and agreement with newly-proposed statements were voted on a 0-10 scale (where 0 = no applicability/agreement and 10 = total applicability/agreement). A mean level of agreement ≥8 was deemed acceptable. RESULTS: The consensus threshold was reached for only 4 of the 12 EULAR/PReS recommendations and for 25 of the 27 country-specific statements. Poor agreement with EULAR/PReS recommendations was mostly explained by paucity of centres in Italy that possess both paediatric and adult rheumatologists, disagreement about optimal time of transition start and de nition of transition coordinator, diversity between paediatric and adult clinimetric assessments, and lack of administrative and financial support. CONCLUSIONS: This consensus initiative represents an important step forward toward the establishment of a nationwide TC network for YP with JIA in Italy. The main goals established for the future are the identification of adult rheumatology centres that are willing to participate in the TC process, the education of adult rheumatology teams on childhood-onset rheumatic diseases and transition issues, and the increased awareness of public healthcare authorities and other stakeholders about the importance of good-quality TC.
62. Juvenile Idiopathic Arthritis (Jia) Affected Sibling Pairs Present High Correlation for ANA and ILAR Category
- Author
-
giovanni filocamo, Malattia, Clara, Foeldvari, Ivan, Stanevicha, Valda, Nielsen, Susan, Herlin, Troels, Pruunsild, Chris, Zulian, Francesco, Balogh, Zsolt, Dressler, Frank, Rumba, Ingrida, Alpigiani, Maria Giannina, Cortis, Elisabetta, Falcini, Fernanda, Trauzeddel, Ralf, Calcagno, Giuseppina, Lepore, Loredana, Alessio, Maria, Glass, David, Thompson, Susan, Martini, Alberto, Ruperto, Nicolino, Filocamo, G, Malattia, C, Foeldvari, I, Stanevicha, V, Nielsen, S, Herlin, T, Pruunsild, C, Zulian, F, Balogh, Z, Dressler, F, Rumba, I, Alpigiani M., G, Cortis, E, Falcini, F, Trauzeddel, R, Calcagno, G, Lepore, L, Alessio, Maria, Glass, D, Thompson, S, Martini, A, and Ruperto, N.
63. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase
- Author
-
Domenico Del Principe, Elisabetta Cortis, Gian Luigi Marseglia, Alberto Villani, Elisabetta Straface, Ugo Giordano, Maya El Hachem, Silvana Martino, Isabella Tarissi de Jacobis, Alessandro Rimini, Savina Mannarino, Aurelio Secinaro, Donato Rigante, Rosa Maria Dellepiane, Marzia Duse, Donatella Pietraforte, Rossella Massaro, Grazia Bossi, Alessandra Marchesi, Walter Malorni, Christian Pescosolido, Fabio Cardinale, Susanna Esposito, Patrizia Salice, Fabrizio De Benedetti, Giovanni Corsello, Giulia Marucci, Sabrina Buonuomo, Fernanda Falcini, Maria Cristina Maggio, Andrea Zorzi, Livio D’Isanto, Maria Cristina Pietrogrande, Marchesi, Alessandra, Tarissi De Jacobis, Isabella, Rigante, Donato, Rimini, Alessandro, Malorni, Walter, Corsello, Giovanni, Bossi, Grazia, Buonuomo, Sabrina, Cardinale, Fabio, Cortis, Elisabetta, De Benedetti, Fabrizio, De Zorzi, Andrea, Duse, Marzia, Del Principe, Domenico, Dellepiane, Rosa Maria, D'Isanto, Livio, El Hachem, Maya, Esposito, Susanna, Falcini, Fernanda, Giordano, Ugo, Maggio, Maria Cristina, Mannarino, Savina, Marseglia, Gianluigi, Martino, Silvana, Marucci, Giulia, Massaro, Rossella, Pescosolido, Christian, Pietraforte, Donatella, Pietrogrande, Maria Cristina, Salice, Patrizia, Secinaro, Aurelio, Straface, Elisabetta, and Villani, Alberto
- Subjects
Male ,Pediatrics ,Review ,Severity of Illness Index ,0302 clinical medicine ,Retrospective Studie ,Epidemiology ,030212 general & internal medicine ,Disease management (health) ,Coronary artery abnormalitie ,Children ,Societies, Medical ,Randomized Controlled Trials as Topic ,Pediatric ,lcsh:RJ1-570 ,Disease Management ,Immunoglobulins, Intravenous ,General Medicine ,Prognosis ,Settore MED/38 ,Treatment Outcome ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Italy ,Meta-analysis ,Acute Disease ,Practice Guidelines as Topic ,Disease Progression ,Female ,Coronary artery abnormalities ,Aspirin ,Intravenous immunoglobulin ,Kawasaki disease ,Human ,medicine.medical_specialty ,Prognosi ,Mucocutaneous Lymph Node Syndrome ,Risk Assessment ,03 medical and health sciences ,030225 pediatrics ,Severity of illness ,medicine ,Humans ,Risk factor ,Retrospective Studies ,aspirin ,children ,coronary artery abnormalities ,intravenous immunoglobulin ,pediatrics, perinatology and child health ,business.industry ,lcsh:Pediatrics ,Retrospective cohort study ,medicine.disease ,Immunoglobulins, Intravenou ,Pediatrics, Perinatology and Child Health ,perinatology and child health ,Differential diagnosis ,business - Abstract
The primary purpose of these practical guidelines related to Kawasaki disease (KD) is to contribute to prompt diagnosis and appropriate treatment on the basis of different specialists’ contributions in the field. A set of 40 recommendations is provided, divided in two parts: the first describes the definition of KD, its epidemiology, etiopathogenetic hints, presentation, clinical course and general management, including treatment of the acute phase, through specific 23 recommendations. Their application is aimed at improving the rate of treatment with intravenous immunoglobulin and the overall potential development of coronary artery abnormalities in KD. Guidelines, however, should not be considered a norm that limits treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient’s condition, and disease severity or complications.
- Published
- 2018
64. The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
- Author
-
Adele Civino, Claudia Toppino, Francesca Perfetti, Monica Tonelli, Silvia Scala, Alessandro Consolaro, Silvia Magni-Manzoni, Angela Miniaci, Francesca Bovis, Nicolino Ruperto, Patrizia Barone, Angela Pistorio, Donato Rigante, Giovanni Filocamo, Francesco La Torre, Elisabetta Cortis, Alberto Martini, Romina Gallizzi, Fabrizio De Benedetti, Fabrizia Corona, Rolando Cimaz, Sara Pieropan, Rita Consolini, Serena Pastore, Rosa Anna Podda, Angelo Ravelli, Valeria Gerloni, Elisa Patrone, Silvana Martino, Francesco Licciardi, Maria Cristina Maggio, Daniela Tani, Marco Garrone, Consolaro, Alessandro, Bovis, Francesca, Pistorio, Angela, Cimaz, Rolando, De Benedetti, Fabrizio, Miniaci, Angela, Corona, Fabrizia, Gerloni, Valeria, Martino, Silvana, Pastore, Serena, Barone, Patrizia, Pieropan, Sara, Cortis, Elisabetta, Podda, Rosa Anna, Gallizzi, Romina, Civino, Adele, Torre, Francesco La, Rigante, Donato, Consolini, Rita, Maggio, Maria Cristina, Magni-Manzoni, Silvia, Perfetti, Francesca, Filocamo, Giovanni, Toppino, Claudia, Licciardi, Francesco, Garrone, Marco, Scala, Silvia, Patrone, Elisa, Tonelli, Monica, Tani, Daniela, Ravelli, Angelo, Martini, Alberto, and Ruperto, Nicolino
- Subjects
Gerontology ,Male ,Parents ,Patient Reported Outcome Measure ,Psychometrics ,Health Status ,Arthritis ,Juvenile ,Predictive Value of Test ,Health Statu ,Disability Evaluation ,0302 clinical medicine ,Medicine ,Immunology and Allergy ,Functional ability ,Age of Onset ,Child ,JAMAR ,Patient ,Prognosis ,Disease status ,Health Related Quality of Life ,Juvenile idiopathic arthritis ,Adolescent ,Arthritis, Juvenile ,Case-Control Studies ,Child, Preschool ,Cultural Characteristics ,Female ,Humans ,Italy ,Patients ,Predictive Value of Tests ,Quality of Life ,Reproducibility of Results ,Rheumatology ,Translating ,Patient Reported Outcome Measures ,Cultural Characteristic ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Predictive value of tests ,Case-Control Studie ,Psychometric ,Human ,medicine.medical_specialty ,Prognosi ,Immunology ,Reproducibility of Result ,03 medical and health sciences ,Juvenile idiopathic arthriti ,Quality of life (healthcare) ,Disease status, Functional ability, Health Related Quality of Life, JAMAR, Juvenile idiopathic arthritis, Adolescent, Age of Onset, Arthritis, Juvenile, Case-Control Studies, Child, Child, Preschool, Cultural Characteristics, Female, Health Status, Humans, Italy, Male, Parents, Patients, Predictive Value of Tests, Prognosis, Psychometrics, Quality of Life, Reproducibility of Results, Rheumatology, Translating, Disability Evaluation, Patient Reported Outcome Measures ,030225 pediatrics ,Internal medicine ,Validation Studies ,Disease statu ,Preschool ,030203 arthritis & rheumatology ,business.industry ,medicine.disease ,Parent ,Age of onset ,business - Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Italian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and discriminant validity). A total of 1296 JIA patients (7.2% systemic, 59.5% oligoarticular, 21.4% RF negative polyarthritis, 11.9% other categories) and 100 healthy children, were enrolled in 18 centres. The JAMAR components discriminated well healthy subjects from JIA patients except for the Health Related Quality of Life (HRQoL) Psychosocial Health (PsH) subscales. All JAMAR components revealed good psychometric performances. In conclusion, the Italian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
- Published
- 2018
65. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
- Author
-
Marta Torcoletti, Achille Marino, Francesco La Torre, Giovanni Conti, Patrizia Barone, Donato Rigante, Francesco Zulian, Francesca Rovelli, Angelo Ravelli, Fabrizio De Benedetti, Gianfranco D'Angelo, Adele Civino, Alessandro De Fanti, Rebecca Nicolai, Valeria Gerloni, Irene Pontikaki, Silvia Magni-Manzoni, Francesca Bovis, Maria Cristina Maggio, Nicolino Ruperto, Serena Pastore, C Fede, Denise Pires Marafon, Alberto Martini, Chiara Sandrin, Fabrizia Corona, Romina Gallizzi, Sergio Davì, MG Alpigiani, Rita Consolini, Sara Verazza, Alessandro Consolaro, Giorgia Martini, Antonella Insalaco, Mauro Jorini, Alma Nunzia Olivieri, Rolando Cimaz, Rosanna Podda, Valentina Muratore, Luciana Breda, Marco Cattalini, Elisabetta Cortis, Verazza, Sara, Davì, Sergio, Consolaro, Alessandro, Bovis, Francesca, Insalaco, Antonella, Magni Manzoni, Silvia, Nicolai, Rebecca, Marafon, Denise Pire, De Benedetti, Fabrizio, Gerloni, Valeria, Pontikaki, Irene, Rovelli, Francesca, Cimaz, Rolando, Marino, Achille, Zulian, Francesco, Martini, Giorgia, Pastore, Serena, Sandrin, Chiara, Corona, Fabrizia, Torcoletti, Marta, Conti, Giovanni, Fede, Claudia, Barone, Patrizia, Cattalini, Marco, Cortis, Elisabetta, Breda, Luciana, Olivieri, Alma Nunzia, Civino, Adele, Podda, Rosanna, Rigante, Donato, La Torre, Francesco, D'Angelo, Gianfranco, Jorini, Mauro, Gallizzi, Romina, Maggio, Maria Cristina, Consolini, Rita, De Fanti, Alessandro, Muratore, Valentina, Alpigiani, Maria Giannina, Ruperto, Nicolino, Martini, Alberto, Ravelli, Angelo, Verazza, S., Davì, S., Consolaro, A., Bovis, F., Insalaco, A., Magni-Manzoni, S., Nicolai, R., Marafon, D., De Benedetti, F., Gerloni, V., Pontikaki, I., Rovelli, F., Cimaz, R., Marino, A., Zulian, F., Martini, G., Pastore, S., Sandrin, C., Corona, F., Torcoletti, M., Conti, G., Fede, C., Barone, P., Cattalini, M., Cortis, E., Breda, L., Olivieri, A., Civino, A., Podda, R., Rigante, D., La Torre, F., D'Angelo, G., Jorini, M., Gallizzi, R., Maggio, M., Consolini, R., De Fanti, A., Muratore, V., Alpigiani, M., Ruperto, N., Martini, A., and Ravelli, A.
- Subjects
Male ,Biologic therapie ,Biologic therapies ,Etanercept ,Juvenile idiopathic arthritis ,Pediatric rheumatology ,TNF inhibitors ,Adolescent ,Antirheumatic Agents ,Arthritis, Juvenile ,Child ,Child, Preschool ,Cross-Sectional Studies ,Drug Substitution ,Female ,Humans ,Methotrexate ,Patient Outcome Assessment ,Retrospective Studies ,Treatment Outcome ,Pediatrics, Perinatology and Child Health ,Rheumatology ,Immunology and Allergy ,Arthritis ,Juvenile ,Pediatrics ,Inflammatory bowel disease ,Settore MED/38 - Pediatria Generale E Specialistica ,0302 clinical medicine ,Quality of life ,Retrospective Studie ,030212 general & internal medicine ,Antirheumatic Agent ,Perinatology and Child Health ,3. Good health ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Research Article ,Human ,medicine.drug ,medicine.medical_specialty ,03 medical and health sciences ,Juvenile idiopathic arthriti ,Internal medicine ,medicine ,Pediatrics, Perinatology, and Child Health ,Adverse effect ,Preschool ,Cross-Sectional Studie ,030203 arthritis & rheumatology ,business.industry ,Retrospective cohort study ,medicine.disease ,Discontinuation ,Physical therapy ,business ,TNF inhibitor - Abstract
Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three groups received a retrospective assessment; patients in group 1 also underwent a cross-sectional assessment. Results: 1038 patients were enrolled by 23 centers: 422 (40.7%) were in group 1, 462 (44.5%) in group 2, and 154 (14.8%) in group 3. Median duration of ETN therapy was 2.5 years. At cross-sectional assessment, 41.8% to 48.6% of patients in group 1 met formal criteria for inactive disease, whereas 52.4% of patients in group 2 and 55.8% of patients in group 3 were judged in clinical remission by their caring physician at last visit. A relatively greater proportion of patients with systemic arthritis were discontinued or lost to follow-up. Parent evaluations at cross-sectional visit in group 1 showed that 52.4% of patients had normal physical function, very few had impairment in quality of life, 51.2% had no pain, 76% had no morning stiffness, and 82.7% of parents were satisfied with their child's illness outcome. Clinically significant adverse events were reported for 27.8% of patients and ETN was discontinued for side effects in 9.5%. The most common adverse events were new onset or recurrent uveitis (10.2%), infections (6.6%), injection site reactions (4.4%), and neuropsychiatric (3.1%), gastrointestinal (2.4%), and hematological disorders (2.1%). Ten patients developed an inflammatory bowel disease and 2 had a malignancy. One patient died of a fulminant streptococcal sepsis. Conclusions: Around half of the patients achieved complete disease quiescence under treatment with ETN. The medication was overall well tolerated, as only one quarter of patients experienced clinically significant adverse events and less than 10% had treatment discontinued for toxicity.
- Published
- 2016
66. Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey.
- Author
-
Ravelli A, Sinigaglia L, Cimaz R, Alessio M, Breda L, Cattalini M, Consolaro A, Conti F, Cortis E, D'Angelo S, De Benedetti F, Doria A, Ferrari C, Gallizzi R, Govoni M, Gremese E, Iannone F, La Torre F, Maggio MC, Perricone R, Pontikaki I, Rossi F, Salaffi F, Simonini G, and Caporali R
- Subjects
- Adolescent, Adult, Child, Consensus, Humans, Italy, Surveys and Questionnaires, Arthritis, Juvenile, Rheumatology, Transition to Adult Care, Transitional Care
- Abstract
Objectives: To present the results of a Delphi consensus survey among Italian paediatric and adult rheumatologists on transitional care (TC) of young people (YP) with juvenile idiopathic arthritis (JIA)., Methods: A taskforce of 27 paediatric and adult rheumatologists evaluated the applicability of the 2016 EULAR/PReS recommendations for TC to the Italian rheumatology practice and healthcare system and formulated additional country-specific statements aimed to increase their suitability. After a two-round discussion, applicability of EULAR/PReS recommendations and agreement with newly-proposed statements were voted on a 0-10 scale (where 0 = no applicability/agreement and 10 = total applicability/agreement). A mean level of agreement ≥8 was deemed acceptable., Results: The consensus threshold was reached for only 4 of the 12 EULAR/PReS recommendations and for 25 of the 27 country-specific statements. Poor agreement with EULAR/PReS recommendations was mostly explained by paucity of centres in Italy that possess both paediatric and adult rheumatologists, disagreement about optimal time of transition start and de nition of transition coordinator, diversity between paediatric and adult clinimetric assessments, and lack of administrative and financial support., Conclusions: This consensus initiative represents an important step forward toward the establishment of a nationwide TC network for YP with JIA in Italy. The main goals established for the future are the identification of adult rheumatology centres that are willing to participate in the TC process, the education of adult rheumatology teams on childhood-onset rheumatic diseases and transition issues, and the increased awareness of public healthcare authorities and other stakeholders about the importance of good-quality TC.
- Published
- 2019
67. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
- Author
-
Verazza S, Davì S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, Nicolai R, Marafon DP, De Benedetti F, Gerloni V, Pontikaki I, Rovelli F, Cimaz R, Marino A, Zulian F, Martini G, Pastore S, Sandrin C, Corona F, Torcoletti M, Conti G, Fede C, Barone P, Cattalini M, Cortis E, Breda L, Olivieri AN, Civino A, Podda R, Rigante D, La Torre F, D'Angelo G, Jorini M, Gallizzi R, Maggio MC, Consolini R, De Fanti A, Muratore V, Alpigiani MG, Ruperto N, Martini A, and Ravelli A
- Subjects
- Adolescent, Child, Child, Preschool, Cross-Sectional Studies, Drug Substitution, Female, Humans, Male, Methotrexate therapeutic use, Patient Outcome Assessment, Retrospective Studies, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Juvenile drug therapy, Etanercept therapeutic use
- Abstract
Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN)., Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three groups received a retrospective assessment; patients in group 1 also underwent a cross-sectional assessment., Results: 1038 patients were enrolled by 23 centers: 422 (40.7%) were in group 1, 462 (44.5%) in group 2, and 154 (14.8%) in group 3. Median duration of ETN therapy was 2.5 years. At cross-sectional assessment, 41.8% to 48.6% of patients in group 1 met formal criteria for inactive disease, whereas 52.4% of patients in group 2 and 55.8% of patients in group 3 were judged in clinical remission by their caring physician at last visit. A relatively greater proportion of patients with systemic arthritis were discontinued or lost to follow-up. Parent evaluations at cross-sectional visit in group 1 showed that 52.4% of patients had normal physical function, very few had impairment in quality of life, 51.2% had no pain, 76% had no morning stiffness, and 82.7% of parents were satisfied with their child's illness outcome. Clinically significant adverse events were reported for 27.8% of patients and ETN was discontinued for side effects in 9.5%. The most common adverse events were new onset or recurrent uveitis (10.2%), infections (6.6%), injection site reactions (4.4%), and neuropsychiatric (3.1%), gastrointestinal (2.4%), and hematological disorders (2.1%). Ten patients developed an inflammatory bowel disease and 2 had a malignancy. One patient died of a fulminant streptococcal sepsis., Conclusions: Around half of the patients achieved complete disease quiescence under treatment with ETN. The medication was overall well tolerated, as only one quarter of patients experienced clinically significant adverse events and less than 10% had treatment discontinued for toxicity.
- Published
- 2016
- Full Text
- View/download PDF
68. Clinical overview and outcome in a cohort of children with polyarteritis nodosa.
- Author
-
Falcini F, La Torre F, Vittadello F, Rigante D, Martini G, Corona F, Buoncompagni A, Alessio M, Cortis E, Insalaco A, Magni-Manzoni S, Breda L, Matucci-Cerinic M, and Zulian F
- Subjects
- Adolescent, Age of Onset, Child, Female, Humans, Italy epidemiology, Male, Organ Dysfunction Scores, Patient Acuity, Prognosis, Remission Induction, Retrospective Studies, Risk Assessment, Secondary Prevention, Time, Vasculitis, Central Nervous System epidemiology, Vasculitis, Central Nervous System physiopathology, Immunosuppressive Agents therapeutic use, Polyarteritis Nodosa complications, Polyarteritis Nodosa diagnosis, Polyarteritis Nodosa drug therapy, Polyarteritis Nodosa epidemiology, Polyarteritis Nodosa physiopathology, Vasculitis, Central Nervous System etiology
- Abstract
Objectives: Polyarteritis nodosa (PAN) is a rare vasculitis in childhood and poor information is known about its long-term outcome. Our aim was to describe the clinical features, at onset and during the disease course, of childhood-onset PAN and identify a potential correlation with persistent organ damage and worse outcome in a cohort of paediatric patients with a confirmed diagnosis of PAN., Methods: A retrospective collection of demographic and clinical data of 52 Caucasian children diagnosed with PAN, fulfilling the EULAR/PRES diagnostic criteria, recruited from eight paediatric rheumatologic centres and one transition unit, was performed. A statistical correlation was made between clinical involvement at onset or during the overall disease course and patients' final outcome., Results: Data from 52 patients (31 males, 21 females) were collected: their mean age at onset was 7.9 years (median 6.3) and mean follow-up period was 6.2 years (median 5.4). At the last follow-up visit, 27 patients (51.9%) were off therapy in clinical remission, 17 (32.7%) were in clinical remission while on medication, and 6 (11.6%) had a persistent or relapsing disease course. Two patients (3.8%) deceased because of severe cerebral involvement. Cranial nerve palsy during the disease course was significantly correlated with a worse prognosis (p=0.011). The presence of nephrogenic hypertension at onset and seizures during the disease course were significantly associated with the development of irreversible organ damage (p= 0.040 and 0.011, respectively)., Conclusions: Childhood PAN is a severe disease with substantial risk of long-term morbidities. In our cohort of patients the worst outcome was significantly correlated with renal and neurological involvement.
- Published
- 2014
69. Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected].
- Author
-
Cortis E, De Benedetti F, Insalaco A, Cioschi S, Muratori F, D'Urbano LE, and Ugazio AG
- Subjects
- Acne Vulgaris drug therapy, Acne Vulgaris genetics, Adaptor Proteins, Signal Transducing genetics, Adolescent, Adult, Arthritis drug therapy, Arthritis genetics, Child, Child, Preschool, Cytoskeletal Proteins genetics, Etanercept, Female, Humans, Male, Pyoderma drug therapy, Pyoderma genetics, Syndrome, Tumor Necrosis Factor-alpha biosynthesis, Acne Vulgaris complications, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Arthritis complications, Immunoglobulin G therapeutic use, Pyoderma complications, Receptors, Tumor Necrosis Factor therapeutic use, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
We report a family with pyogenic sterile arthritis, pyoderna and acne syndrome (PAPA). The proband presented several episodes of sterile pyogenic arthritis and became unresponsive to glucocorticoids. After treatment with the tumor necrosis factor inhibitor etanercept, the disease underwent rapid and sustained clinical remission. Production of tumor necrosis factor-alpha by mononuclear cells of the proband and of the affected relatives was abnormally elevated.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.